Amgen’s Melanoma Vaccine Shows Durable Response; Survival Still A Hurdle
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The vaccine acquired from BioVex at high cost still needs to demonstrate overall survival in Phase III and prove value in an increasingly competitive market for melanoma treatments.